Latest Barda Stories
NESS ZIONA, Israel, September 29, 2014 /PRNewswire/ -- Atox Bio, a clinical stage company developing novel immunomodulators for severe infections, today announced that
MERIDEN, Conn., June 17, 2014 /PRNewswire/ -- Protein Sciences Corporation announced today that BARDA, within the
HINCKLEY, Ohio, March 12, 2014 /PRNewswire/ -- Clinical Research Management, Inc.
Countervail’s advanced development contract with BARDA fully realized is valued at $24.9 million over a five year period.